Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764733 · ClinicalTrials.gov registry record · Phase 4
Bone, Exercise, Alendronate, and Caloric Restriction
A Phase 4 study of Bone Loss, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 900
- Enrollment target
- 2
- Study locations
NCT05764733 is a Phase 4 study of Bone Loss that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 900 participants, above the 198-participant average among 16 other Bone Loss trials with a reported enrollment target (355% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT05764733, a Phase 4 study of Bone Loss, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 900 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bisphosphonate
- BEHAVIORAL Resistance Training/Bone-Loading Exercise
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
North Carolina
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05764733
The ClinicalTrials.gov registry entry for NCT05764733 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 16 other Bone Loss trials with a reported enrollment target (355% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Loss appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05764733 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05764733 about?
NCT05764733 is a clinical study titled "Bone, Exercise, Alendronate, and Caloric Restriction". The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
What is the current status of trial NCT05764733?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 900 participants. The study started on 2023-06-08. Estimated completion is 2027-09.
What conditions does trial NCT05764733 study?
This clinical trial studies the following conditions: Bone Loss.
What interventions are being tested in trial NCT05764733?
The interventions under investigation include: Placebo (OTHER), Bisphosphonate (DRUG), Resistance Training/Bone-Loading Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT05764733?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764733 being conducted?
This trial has 2 study locations across Colorado, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
RECRUITING · Phase 4
-
Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
COMPLETED · Phase 4
-
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
RECRUITING
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.